HEALTHY BRAIN AGING - Starts Here -
Version 4.1.0
January 23, 2024

Information contained in this pamphlet is accurate as of print date. Please confirm with the study coordinator for updates on studies that may not be reflected in this catalog, or visit the CU Alzheimer's and Cognition Center website at:

www.cumemoryresearch.org

The information contained in this catalog is not to be used as medical advice. If you or someone you know is concerned about their memory or brain health, please consult your health care provider.
# Table of Contents

Frequently Asked Questions (FAQ) .......................................................... 4

Observational Research Studies ............................................................. 7

  Bio-AD ................................................................................................. 8
  CSA Study ........................................................................................... 13
  ALLFTD ............................................................................................... 16

Study of Facial Movements and Expressions ....................................... 17

Sleep Study ........................................................................................... 20

Clinical Trials ....................................................................................... 25

  SESAD .................................................................................................. 26
  SHIMMER ............................................................................................ 30
  ENVISION ........................................................................................... 31
Frequently Asked Questions

I am interested in participating in research, but don’t know where to start. What should I do?

A great place to start would be to contact our recruitment specialists at NeuroResearch@cuanschutz.edu or 303-724-4644. They can tell you more about research in general and answer any other questions you may have.

I think I might be eligible for one of these studies. What is the next step in the process?

Call or email the coordinator listed for the study you think you are interested in. The coordinator will go through a brief pre-screening questionnaire with you over the phone—takes about five minutes—to see if you are a good fit. If you meet the initial screening requirements, the coordinator will work with you to schedule a more detailed, in-person screening visit. You can also reach out to our recruitment specialists at NeuroResearch@cuanschutz.edu or call them at 303-724-4644 if you are interested in more than one study.

What do I do if I want to participate in research, but none of these studies are for me?

The Neurology Department has many ongoing studies not listed in this catalog that investigate other neurological disorders and diseases. We would be happy to talk with you more and learn what type of research you are interested in, and see if we can find a study for you. Even if we can’t find a study right now, new studies are always starting in our department, and we can keep your information in our database to contact you in the future. Contact us at: NeuroResearch@cuanschutz.edu or 303-724-4644 or go to www.cumemoryresearch.org

I really want to get involved in research, but I just don’t have the time right now. What can I do?

Feel free to give us a call anyway! We can take down your information and keep you in our database, so when you have more time, we can give you a call.

Is participating in research voluntary?

Yes! All research is voluntary. You can stop participation and withdraw from a study at any time, and there will be no hard feelings.
Frequently Asked Questions

What is the CU Alzheimer’s and Cognition Center?

The University of Colorado Alzheimer’s and Cognition Center (CUACC) is located at the CU Anschutz Medical Campus and is part of the School of Medicine, Department of Neurology. We emphasize both research and clinical care using a team approach, with laboratory research scientists and neurology clinicians, all working collaboratively on the science and treatments of neurodegenerative diseases.

Does the CUACC have a memory clinic?

Yes, we do. The University of Colorado Neurobehavior and Memory Disorders Clinic is a key component of the University of Colorado Alzheimer’s and Cognition Center, along with research. At our Memory Disorders Clinic in the Central Park neighborhood of Denver, we see over 2500 unique patient visits each year with memory complaints and neurodegenerative diseases.

How do I schedule an appointment with the Memory Disorders Clinic?

To make an appointment, call the Neurobehavior and Memory Disorders Clinic at 720-848-2080 and tell them you would like to see a behavioral neurologist. A referral from your primary care physician is encouraged but not required.

Where is the Memory Disorders Clinic located?

3055 Roslyn Street, Suite 120
Denver, CO 80238

What insurances does the Memory Disorders Clinic take?

The Neurobehavior and Memory Disorders Clinic accepts all insurances accepted by UCHealth, which includes Medicare and Medicaid. Contact UCHealth Billing and Pricing at 1-866-249-6045 to find out more about insurance coverage.

What does a visit with a behavioral neurologist look like?

Our clinicians in the Neurobehavior and Memory Disorders Clinic start with a thorough evaluation, a process which often includes detailed cognitive testing by a Neuropsychologist. Each patient gets a specific treatment plan, developed to meet that individual’s needs. For more information, visit our clinic website at: cuanschutz.edu/alzheimer/clinic
Observational Studies

The following section of studies are called observational studies. Observational studies do not involve an intervention (i.e., a possible new drug or treatment). Instead, people volunteer their time to let researchers observe and study certain behavior patterns and collect biological samples such as blood samples, brain images through MRI or PET scans, and cerebrospinal fluid (CSF) samples. Observational studies can be, but are not always, longitudinal, meaning the same person returns at a certain point in the future to do the same tasks again, so that responses can be compared over time.

The observational studies we do here at the CU Alzheimer’s and Cognition Center aim to carefully characterize a group of aging adults so that we can better understand what may put certain individuals at risk for later cognitive decline and how to prevent it. Our current observational studies follow aging adults – both symptomatic participants, meaning adults who have been diagnosed with mild cognitive impairment (MCI), Alzheimer’s disease, or another form of dementia, adults with down syndrome, and asymptomatic participants, meaning healthy aging adults with no current symptoms.
Longitudinal Biomarker and Clinical Phenotyping (Bio-AD)

**Title:** Longitudinal Biomarker and Clinical Phenotyping Research Study

**Principal Investigator:** Dr. Brianne M. Bettcher, PhD

**Protocol:** COMIRB #15-1774

---

For more information about the research study, please contact:

**Study Coordinator:** Neurology Research Partners

**Email:** bioad@cuanschutz.edu

**Phone:** 303-724-4644

**Website:** ColoradoAgingBrain.org

---

**Major Goals of this Research Study**

♦ Help understand why Alzheimer’s disease and its symptoms differ between aging adults.

♦ Identify different "biological footprints" that can help predict individuals most likely to develop Alzheimer’s disease, and those most likely to be protected.

♦ Collect important data on brain aging to be used by researchers to: determine who is at most risk for Alzheimer’s disease and why, to improve early diagnosis of neurodegenerative diseases in aging adults, and to inform the development of novel treatments and therapies.
Why Is this Research Important?

This research study is a longitudinal study, meaning participants return multiple times over the course of four years. Longitudinal studies of aging and Alzheimer’s disease are important as we expand our understanding of the aging process and of factors that put individuals at greater risk for cognitive decline. Participants in this research study will provide us with critical information about aging trajectories, so that we as researchers can learn more about what puts an individual at risk for Alzheimer’s disease and related dementias, what factors protect an individual against developing symptoms, and what screening methods are needed to identify risk factors early enough so that we can enroll someone in a clinical trial before they begin to show symptoms.
Inclusion/Exclusion Criteria

You may be eligible for this research study if you:

◊ Have a study partner available to complete a questionnaire about your functional abilities each year

We are currently recruiting the following groups*

| Healthy older adults from diverse backgrounds, 60 years and older | Adults w/ a confirmed diagnosis from a doctor of Alzheimer’s disease (AD) or Mild Cognitive Impairment due to AD, ages 50 and older | Adults diagnosed w/ an atypical form of Alzheimer's disease (i.e., Posterior Cortical Atrophy) ages 50 and older |

*Depending upon study recruitment needs, active enrollment of some groups may change. Please contact the study coordinator for information.

Please note: This is a brief summary of basic screening criteria. A complete list can be found at http://bit.ly/Bio-AD. Additional things may come up during the course of screening that impact enrollment eligibility, which is ultimately up to the discretion of the study team.
What Will Happen at the Visits

<table>
<thead>
<tr>
<th></th>
<th>Screening and Baseline Visit*</th>
<th>Year 2</th>
<th>Year 3</th>
<th>Year 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility Review</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed Consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical Record Review</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Neurological/Physical Exam</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Questionnaires, Health Survey</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Blood Draw</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Cognitive and Mood Assessments</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Brain MRI</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Partner Questionnaire</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Lumbar Puncture (optional)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

*Screening procedures (highlighted gold) may be completed on the same day as aspects of the baseline visit. If you do not meet the screening criteria, you would not complete the remaining baseline visit procedures.

**Time Spent:** All study visit procedures take about 4-5 hours to complete, with an additional hour for visits with an MRI. The study partner questionnaire takes about 30 minutes and may be able to be done over the phone. The study visit will be repeated every year, requiring about the same amount of time.

**Compensation:** This study does not provide compensation. Participant will receive:

- Snacks and Refreshments
Conversational Speech Analysis (CSA) Research Study

**Title:** Conversational Speech in the Diagnosis of Neurocognitive Disorders

**Principal Investigator:** Dr. Peter Pressman, MD

**Protocol:** COMIRB #18-0456

For more information about the research study, please contact:

**Study Coordinator:** Francesca Dino

**Email:** Francesca.Dino@cuanschutz.edu

**Phone:** 303-724-6103

**Website:** www.cumemoryresearch.org

**Major Goals of this Research Study**

◊ Learn more about how speech changes over time in adult populations.
◊ Understand more about how changes in speech reflect changes in cognition.
◊ Develop diagnostic tools that can be used by primary care providers for early recognition of Alzheimer's disease and related disorders.
Conversational speech, or the speech that happens spontaneously between two people, such as a patient and their doctor, may show changes as a result of neurological disease. These changes may occur not just in what the person says, but how they say it. This research study is important because it hopes to help build diagnostic tools that can identify these changes in conversational speech to facilitate earlier and more accurate recognition of Alzheimer’s disease and related disorders. This is important, because using elements of conversational speech such as tone of voice and duration of speaking could be a cheap, non-invasive way to gather information that can be used to detect cognitive changes earlier, as well as direct medical interventions that will help slow or prevent the progression of neurological disease.
Inclusion/Exclusion Criteria

You may be eligible for this study if you:

♦ Are between the ages of 40-95
♦ Have a reliable study partner who you have known for at least 1 year
♦ Are primarily English speaking, without distinctive regional or international dialect

Please note: This is a brief summary of basic screening criteria. A complete list can be found at http://bit.ly/speech-study. Additional things may come up during the course of screening that impact enrollment eligibility, which is ultimately up to the discretion of the study team.

What Will Happen at the Visit

<table>
<thead>
<tr>
<th></th>
<th>Screening and Baseline Visit*</th>
<th>12-month Follow-up Visit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility Review</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Informed Consent</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Hearing Test</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Recording of Conversation</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Physiological recordings (heart rate, etc.)</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Language and Emotion tasks</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Cognitive Testing**</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

*If you do not meet the screening criteria (determined during procedures highlighted in gold), you would not complete the rest of the visit.

**Cognitive testing procedures may vary based on prior participation in CUACC research studies (e.g. Bio-AD, LIIA).

Time Spent: The study visit lasts approximately 6-8 hours. The visit will be repeated two years later, requiring about the same amount of time. Time spent may be shortened based on prior participation in CUACC research studies.

Compensation: A $40 gift card will be given to participants.
ALLFTD

**Title:** ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

**Sponsor:** Mayo Clinic

**Location:** University of Colorado Denver

**Study Location Principal Investigator:** Peter Pressman, MD

**Contact:** Danelle (Ellie) Carter

**Email:** Danelle.Carter@cuanschutz.edu

**ClinicalTrials.gov Identifier:** NCT04363684

**ALLFTD Study Website:** [https://www.allftd.org/](https://www.allftd.org/)

**Brief Summary:** The ARTFL LEFFTDS Longitudinal Frontotemporal Dementia (ALLFTD) study aims to evaluate sporadic (s-) and familial (f-) frontotemporal lobar degeneration (FTLD) patients and asymptomatic family members of f-FTLD patients, characterizing the cohorts longitudinally and informing clinical trial design. The study has two arms: a “longitudinal arm” involving a comprehensive assessment of clinical, functional, imaging, and biofluid data collection annually, and a “biofluid-focused arm” involving limited clinical data to accompany biospecimen collection. For more information: [https://www.allftd.org/](https://www.allftd.org/)

**Ages Eligible for Study:** 18 Years and older
Study of Facial Movements and Expressions

Title: Timing of Facial Movements for Posed and Spontaneous Facial Expressions

Principal Investigator: Dr. Peter Pressman, MD

Protocol: COMIRB# 17-0599

For more information about the research study, please contact:

Study Coordinator: Francesca Dino

Email: Francesca.Dino@cuanschutz.edu

Phone: 303-724-6103

Website: www.cumemoryresearch.org

Major Goals of this Research Study

◊ Better understand the neurology behind facial expressions using high speed videography, such as which part of the brain is responsible for different expressions.
◊ Learn more about how neurological disorders may impact a person’s facial movements and expressions.
◊ Develop the groundwork for a diagnostic tool that would detect differences between a person’s facial movements/expressions and their emotions.
Why Is this Research Important?

The facial movements and expressions a person makes gives insight into their emotions and what they are thinking. They can also be an indicator for caregivers and physicians for how some neurological conditions are affecting a person’s ability to feel emotions and empathize. This research study will allow research to learn more about the science of these movements and how our faces move, and the neurology behind it. This is important because there may be some neurological conditions where a person’s outward facial expression may not reflect their internal emotions. If scientists understand better how these expressions are made, they can develop tools to detect if a person’s disorder is affecting their ability to show emotion through facial movements and expressions.
Inclusion/Exclusion Criteria

You may be eligible for this research study if you:

◊ Are between 18-95 years old
◊ Have no documented dependency on substances or medications
◊ Have no documented history of significant facial fractures

Please note: This is a brief summary of basic screening criteria. A complete list can be found at http://bit.ly/facialmovements.

Additional things may come up during the course of screening that impact enrollment eligibility, which is ultimately up to the discretion of the study team.

What Will Happen at the Visit

<table>
<thead>
<tr>
<th>Study Visit*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility Review</td>
</tr>
<tr>
<td>Informed Consent</td>
</tr>
<tr>
<td>Medical History</td>
</tr>
<tr>
<td>Brief Neurological Exam</td>
</tr>
<tr>
<td>Health Questionnaires</td>
</tr>
<tr>
<td>Facial Expression Recording</td>
</tr>
</tbody>
</table>

*If you do not meet the screening criteria (determined during procedures highlighted in gold), you would not complete the rest of the visit.

Time Spent: The one study visit that will take place lasts approximately one hour.

Compensation: This study does not provide compensation. Snacks and refreshments will be provided.
Study of Sleep in Healthy Aging and Neurological Conditions

**Title:** Measurement of Sleep and Circadian Physiology in Aging, Neurodegeneration, and Neurological Injury

**Principal Investigator:** Dr. Brice McConnell, MD, PhD

**Protocol:** COMIRB #19-0343

For more information about the research study, please contact:

**Study Contact:** Neurology Research Partners

**Email:** NeuroResearch@cuanschutz.edu

**Phone:** 303-724-4644

**Website:** www.cumemoryresearch.org

Major Goals of this Research Study

- Visualize the relationship between deep sleep and the immune system by using the DREEM device, which records participants’ brain activity during sleep.
- Learn more about the neuroprotective aspects of sleep as it relates to alzheimer’s disease and brain injuries.
- Further understand what components of sleep may be contributing to a person’s risk for cognitive decline.
Why Is this Research Important?

Researchers believe that sleep has important brain maintenance and restorative functions for a person’s brain health. Specifically they are interested in what is called slow wave sleep, or deep sleep, that may be necessary for body to regulate different systems, such as your immune system. While these functions work well when people are younger, they believe that this function may not perform as well as we age. This may be one of the factors that contributes to changes in your brain health that could lead to Alzheimer’s or other kinds of brain conditions.

This research study is important because it will allow researchers to learn more about how looking at recordings of someone’s sleep can provide insight into their overall brain health and how the brain maintenance system is functioning. The brain maintenance system of sleep is a novel system that requires a lot more research to understand, but may prove to be a predictor of a person’s cognitive functioning down the road. This research study puts researchers on the path to understanding how sleep may be used as a predictor for cognitive functioning and other neurodegenerative problems.
Inclusion/Exclusion Criteria

You may be eligible for this research study if you:

◊ Have no electronic devices implanted above the neck
◊ Have no eczema or skin sensitivity

We are currently recruiting the following groups*

Healthy older adults who are currently enrolled in or who recently completed either the Bio-AD study (COMIRB #15-1774) or the LIIA study (COMIRB #18-2607)  
Adults w/ a diagnosis of Alzheimer’s disease or Mild Cognitive Impairment who are currently enrolled in or who recently completed the Bio-AD study (COMIRB #15-1774)  
Adults diagnosed with an mTBI who are currently enrolled in or who recently completed the ImTAB study (COMIRB #19-1423)

*Depending upon study recruitment needs, active enrollment of some groups may change. Please contact the study coordinator for information.

Please note: This is a brief summary of basic screening criteria. A complete list can be found at http://bit.ly/CUACC-sleep. Additional things may come up during the course of screening that impact enrollment eligibility, which is ultimately up to the discretion of the study team.
## What Will Happen at the Visit

<table>
<thead>
<tr>
<th>Activity</th>
<th>Screening Visit†</th>
<th>Visit 2</th>
<th>At home nights 2-7</th>
<th>Visit 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility Review</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed Consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health Questionnaires</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Training on DREEM Device &amp; Distribution</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleep with DREEM Device to Record Brain Waves</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Complete Sleep Diary</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Return Equipment</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Feedback on Quality of Sleep Recordings</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Review Personal Sleep Data with Study Staff</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

Based on recording quality, study staff may ask for up to two additional sessions to be completed. There are also optional study procedures not listed here that can be completed if the participant chooses to do so.

Please note that participants will have the option to complete all study visits virtually via Zoom.

*If you do not meet the screening criteria (determined during procedures highlighted in gold), you would not complete the rest of the visits and participation in the study would end. Screening Visit and Visit 2 can be combined in one day.

**Time Spent:** Approximately 2-3 hours will be spent in-person with the study staff.

**Compensation:** Participant will be given $10 per night wearing the DREEM device.
Clinical Trials

The studies in this section are clinical trials. Clinical trials study an intervention, such as a drug or a device, that could produce a potential change in the way a disease or medical condition is detected, prevented, managed, or treated. The intervention can be brand new, or it could be something that has been used before to treat other diseases but may now be able to used for a different disease. The purpose of clinical trials are to study the 1. safety of the intervention, and 2. the efficacy, or effectiveness, of the intervention. Clinical trials go through multiple phases before the intervention is determined to be able to be made available to the public.

**PLEASE READ:** The interventions listed in this section do not indicate evaluation or approval by the Food and Drug Administration (FDA). There are risks and potential benefits associated with every clinical trial, and we recommend speaking at length with the study coordinator, your health care provider, and any other interested parties within your family or social circle before participating in a trial.
Title: Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer’s Disease (SESAD)

Principal Investigator: Peter Pressman, MD

Protocol: COMIRB #19-2727

For more information about the research study, please contact:

Study Contact: Neurology Research Partners

Email: NeurologyResearchPartners@cuanschutz.edu

Phone: 303-724-4644

Website: www.cumemoryresearch.org

Co-Investigator/Study Sponsor: Huntington Potter, PhD

Major Goals of this Research Study

◊ Learn more about the safety and effectiveness of a drug called sargramostim for improving cognitive function and memory in people with Alzheimer’s disease. (Sargramostim is an investigational drug, meaning it has not been approved by the FDA to treat Alzheimer’s).

◊ Find out more about how sargramostim works within the body over a longer time period than previously studied.
Why Is this Research Important?

Alzheimer’s disease is a major medical problem in the elderly, affecting 12% of those over age 65 and 40-50% of those over age 85. Current treatments offer minor benefits in slowing the development of memory problems but do not stop or reverse the damage from the disease.

This research study is important because its purpose is to determine if injections of a medicine called sargramostim in people with Alzheimer’s disease is safe and effective in improving cognitive function and memory and to evaluate its safety (side effects). Sargramostim has not been FDA approved as a safe or effective treatment for people with Alzheimer’s Disease.
Inclusion/Exclusion Criteria

You may be eligible for this research study if you:

◊ Are between the ages of 60-85
◊ Have a diagnosis of mild-to-moderate Alzheimer’s disease (AD)
◊ Are willing and able to have weekly blood draws at a local LabCorp
◊ Are willing and able to have an MRI and PET scan
◊ Do not have a first degree relative diagnosed with AD before 55 years of age
◊ Have a study partner willing to give daily injections after training

Please note: This is a brief summary of basic screening criteria. A complete list can be found at http://bit.ly/SESAD.

Additional things may come up during the course of screening that impact enrollment eligibility, which is ultimately up to the discretion of the study team.

What Will Happen at the Screening Visit

<table>
<thead>
<tr>
<th></th>
<th>Tier 1</th>
<th>Tier 2</th>
<th>Tier 3</th>
<th>Tier 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility Review</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed Consent</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brief Cognitive Screening Exam</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Physical/Neurological Exam</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Heart Tracing (ECG)</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Medical History and Medication Review</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Blood Draw</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRI</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Lumbar Puncture (LP) or Amyloid PET Scan</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Optional Sub-Study (Either the LP or Amyloid PET not done at tier 3)</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

Screening visit will be split up into 3-4 visits over 8 weeks. If you do not meet the screening criteria (determined during procedures highlighted in gold) in tier 1, you would not complete tier 2, if you do not meet criteria in tier 2, you would not complete tier 3. If screening criteria in any tier is not met, participation will end.
What Will Happen during Treatment Period

If determined to be eligible during screening, you will be assigned to one of two arms of the study: 1) receives study medication; 2) receives placebo (a pill or a liquid that looks like medicine but is not real). The following will happen for both:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Baseline Visit</th>
<th>Weeks 1-24</th>
<th>End of Treatment</th>
<th>45 day Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Side Effect/Medication Review</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Physical/Neurological Exam</td>
<td>X</td>
<td>At Week 12</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Heart Tracing (ECG)</td>
<td></td>
<td>At Week 12</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Cognitive Testing/Health Surveys</td>
<td>X</td>
<td>At Week 12</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Study Partner Questionnaires</td>
<td>X</td>
<td>At Week 12</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Blood Draw and Vital Signs</td>
<td>X</td>
<td>2x a Week</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Study Partner Injection Training</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injection of study drug</td>
<td>X</td>
<td>5 Days/Week</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain MRI</td>
<td>X</td>
<td>At Week 12</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Lumbar Puncture and/or Amyloid PET</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>FDG PET scan</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

There are also optional study procedures not listed here that can be completed. After initial screenings at the CU Anschutz campus in Aurora, CO, participants will be able to have a weekly home nursing visit each week to provide supplies and draw blood (second blood draw will occur at a local Labcorp). Visits to campus during the study will be required for procedures that cannot be done at home.

**Time Spent:** The research study (including screening) will take approximately 9 months to complete. Individual visit length will vary based on procedures completed, with the majority of weekly study visits lasting about 90 minutes.

**Compensation:** Participant will be given $75 at the end of the 24-week treatment period, $25 after the 45 day follow-up, $75 after each lumbar puncture, or $125 after each Amyloid PET scan for a maximum of $500.
SHIMMER

Title: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies (COG1201)

Sponsors and Collaborators: Cognition Therapeutics, National Institute on Aging (NIA)

Study Location Principal Investigator: Samantha K Holden

Contact: Franklin Roberts

Phone: 303-724-4644

Email: NeuroResearch@cuanschutz.edu

ClinicalTrials.gov Identifier: NCT05225415

SHIMMER Study Website: https://shimmerdlbstudy.com/

Brief Summary: Multi-center, randomized, double-blind, placebo-controlled, 6-month study in subjects with mild to moderate Dementia with Lewy Bodies.

Ages Eligible for Study: 50 years to 85 years
ENVISION

**Title:** A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer’s Disease

**Sponsors and Collaborators:** Biogen

**Principal Investigator:** Victoria Pelak, MD

**Contact:** Biogen

**Phone:** 866-633-4636

**Email:** clinicaltrials@biogen.com

**ClinicalTrials.gov Identifier:** NCT05310071

**Brief Summary:** The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer’s disease.

**Ages Eligible for Study:** 60 Years to 85 Years